Christopher Manley, MD
Pulmonary Disease · Philadelphia, PANPI 1992936330
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $228,262 of the $261,693 with a category attached, or 87.2%. Johnson & Johnson accounts for 68.2% of it on its own, with 15 other manufacturers making up the rest. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $955.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$178K
- Medical Device Business Services, Inc.$61K
- Auris Health, Inc.$10K
- Janssen Scientific Affairs, LLC$6K
- Boston Scientific$4K
- Noah Medical Corporation$918
- plus $2K from 10 others
Across 24 payments — averaging $13,261 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$199K
- Johnson & Johnson$63K
- Mauna Kea Technologies, Inc.$56K
What the payments were for
- Consulting fees$228,26287%
- Speaking & faculty fees$1,0500%
- Travel & lodging$24,7189%
- Food & beverage$7,6643%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 145 | $178,356 |
| Medical Device Business Services, Inc. | 89 | $61,437 |
| Auris Health, Inc. | 6 | $9,737 |
| Janssen Scientific Affairs, LLC | 1 | $6,060 |
| Boston Scientific | 9 | $3,586 |
| Noah Medical Corporation | 6 | $918 |
| Ethicon Endo-surgery Inc. | 2 | $904 |
| Daiichi Sankyo Inc. | 6 | $147 |
| AstraZeneca | 1 | $112 |
| Pulmonx Corporation | 1 | $102 |
| Galvanize Therapeutics, Inc | 2 | $93 |
| Intuitive Surgical | 2 | $88 |
| Mauna Kea Technologies, Inc. | 1 | $55 |
| Fujifilm Healthcare Americas Corporation | 1 | $41 |
| Covidien LP | 1 | $40 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$176,920
- MONARCH$63,046
- ACQUIRE$3,226
- GALAXY$171
- IMFINZI$112
- Pulmonx Endobronchial Valve EBV$102
How this compares
$261,693 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $59,062 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $16,516 |
| Spiriva HandihalerTiotropium Bromide | 17 | $8,697 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,561 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $7,237 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $6,651 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $6,099 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 155 | $4,720 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,280 |
| Ventolin HfaAlbuterol Sulfate | 15 | $839 |
| Prednisone | 20 | $157 |
| Montelukast Sodium | 17 | $92 |
| Pantoprazole Sodium | 20 | $60 |
| Azithromycin | 11 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $18 | $82,816140 claims |
| AstraZenecaSymbicort | $112 | $3,28013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
- Jeffrey ThompsonPhiladelphia$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.